Results 11 to 20 of about 20,409 (197)
NAFLD‐related hepatocellular carcinoma: The growing challenge
Hepatology, EarlyView., 2022 Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah +2 more
wiley +1 more source
Haematologica, 2018 We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated myelofibrosis followed in centers affiliated to the French Intergroup of Myeloproliferative ...
Jean-Christophe Ianotto +20 more
doaj +1 more source
The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin [PDF]
Journal of Microbiology and Infectious Diseases, 2012 The pegylated interferon alpha and ribavirin treatment is well established therapy for hepatitis C virus (HCV) infection.During the treatment alanine aminotransferase (ALT) flare may be observed rarely.A 51-year-old female receiving pegylated interferon ...
Hayati Demiraslan +2 more
doaj +3 more sources
Haematologica, 2012 The Philadelphia negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are associated with substantial vascular and transformative complications.
Krisstina Gowin +14 more
doaj +1 more source
Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection [PDF]
Srpski Arhiv za Celokupno Lekarstvo, 2012 Introduction. Chronic hepatitis C virus (HCV) infection can progress to liver cirrhosis that causes bleeding from the gastrointestinal tract, liver failure and primary hepatocellular carcinoma.
Delić Dragan +7 more
doaj +1 more source
Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
Case Reports in Pulmonology, 2015 Hepatitis C virus infection is the leading cause of chronic liver disease in the United States of America. Pegylated interferon α and ribavirin combination is the mainstay of treatment. Severe pulmonary toxicities are rarely reported.
Amit Chopra +3 more
doaj +1 more source
The sustained virologic response of nonresponder hepatitis C virus patients with retreatment
Indian Journal of Pathology and Microbiology, 2011 Background: Pegylated interferon and ribavirin combination therapy remain the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the large number of studies in treatment-naive patients, the effectiveness of retreatment in ...
Sila Cetin Akhan +2 more
doaj +1 more source
Case Reports in Gastroenterology, 2009 The treatment of chronic hepatitis C (CHC) has evolved in the past 15 years and combination of pegylated interferon plus ribavirin is its current standard therapy.
Elson Vidal Martins Jr. +3 more
doaj +1 more source
Журнал инфектологии, 2014 Combination therapy with pegylated interferon-α and ribavirin is the modern standard of chronic hepatitis C treatment [1-3] in Russian Federation [4]. This particular regimen provides achieving of sustained virological response (SVR) in 42-28% of patient
E. Z. Burnevich
doaj +1 more source
Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
Annals of Hepatology, 2010 The effect of interferon alfa against hepatitis C virus has been well documented. However, clinical efficacy is low due to the short interferon residence in the body.
Ricardo Jiménez-Méndez +1 more
doaj +1 more source